1791-753035102015OctAnticancer ResSignatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.544354515443-51The genetic characterization of prostate tumors is important for personalized therapy. The aim of the present study was to investigate the role of previously described prostate cancer-related genes in the genetic characterization of prostate tumors.Forty-two genes were selected for expression analysis (real time-quantitative polymerase chain reaction). One normal prostatic epithelial cell line and three standardized prostate cancer cell lines were used. Twenty-eight patients treated with radical prostatectomy were included in the study.The following genes appeared to be possibly related to the metastatic potential of the tumor: ELOVL fatty acid elongase 7 (ELOVL7), enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), gastrulation brain homeobox 2 (GBX2), golgi membrane protein 1 (GOLM1), homeobox C6 (HOXC6), minichromosome maintenance complex component 6 (MCM6), marker of proliferation Ki-67 (MKI67), mucin 1, cell surface associated (MUC1), MYC binding protein 2, E3 ubiquitin protein ligase (MYCBP2), somatostatin receptor 1 (SSTR1), topoisomerase (DNA) II alpha 170 kDa (TOP2A) and exportin 6 (XPO6). Six genes were differentially expressed in patients with localized and locally advanced cancer (GOLM1, GBX2, XPO6, SSTR1, TOP2A and cell division cycle associated 5, CDCA5) and three genes (HOXC6, Cyclin-dependent kinase inhibitor 2A (CDKN2A) and MYC binding protein 2, E3 ubiquitin protein ligase, MYCBP2) in patients with a low vs. high Gleason grade/sum.Some of the investigated genes show promising prognostic and classification features, which might be useful in a clinical setting, warranting for further validation.Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.TolkachYuriYClinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.MerseburgerAxelAClinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.HerrmannThomasTClinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.KuczykMarkusMClinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.SerthJürgenJClinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.ImkampFlorianFClinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany imkamp.florian@mh-hannover.de.engJournal ArticleResearch Support, Non-U.S. Gov't